HK Stock Market Move | Beijing Chunlizhengda Medical Instruments (01858) rose by over 9% again, overseas business has become an important source of revenue, and third-quarter performance has grown rapidly year-on-year.

Beijing Chunlizhengda Medical Instruments (01858) surged more than 9% again, with a cumulative increase of nearly 25% after the performance report. As of the time of publication, it rose by 7.98% to 20.44 Hong Kong dollars, with a turnover of 98.2915 million Hong Kong dollars. In terms of news, Beijing Chunlizhengda Medical Instruments recently released its performance, with operating income of 756 million yuan in the first three quarters, a year-on-year increase of 48.75%; net profit of 192 million yuan, a year-on-year increase of 213.21%. The operating income in the third quarter was 268 million yuan, a year-on-year increase of 109.51%; the net profit attributable to the parent company was 77.0619 million yuan, turning losses into gains year-on-year. Huatai believes that the rapid growth of performance in the third quarter compared to the same period last year is mainly due to the company's steady progress in expanding international markets, continued growth in export business income, and an increase in sales volume of centralized procurement products. It is optimistic about the continued rapid growth of overseas income and maintains a "buy" rating. The bank pointed out that the company is actively developing its international market business, with rapid growth in overseas income becoming an important source of revenue. The company's hip, knee, and spine series products have all successfully passed CE annual system audits and supervision audits. The knee joint prosthesis system has obtained approval from the US FDA510 (K), indicating that the company's technological advantages have reached an internationally leading level, with strong international market competitiveness, laying the foundation for the continuous increase in the company's international sales. The overseas business continues to expand, and a rapid growth in overseas performance over the next 25 years is expected.